Table 2.
Incidence of all‐cause mortality and MACE
| Total (n = 780,785) | Candesartan (n = 58,892) | Fimasartan (n = 21,041) | Irbesartan (n = 37,170) | Losartan (n = 298,461) | Olmesartan (n = 100,348) | Telmisartan (n = 125,730) | Valsartan (n = 139,143) | p value* | |||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| n | % | n | % | n | % | n | % | n | % | n | % | n | % | n | % | ||
| All‐cause mortality | 22,291 | 2.9 | 1701 | 2.9 | 473 | 2.3 | 1080 | 2.9 | 9566 | 3.2 | 2619 | 2.6 | 3114 | 2.5 | 3738 | 2.7 | <0.001 |
| MACE | 42,216 | 5.4 | 3445 | 5.9 | 961 | 4.6 | 2293 | 6.2 | 16,932 | 5.7 | 5119 | 5.1 | 6159 | 4.9 | 7307 | 5.3 | <0.001 |
| Cardiac death | 4121 | 0.53 | 325 | 0.55 | 76 | 0.36 | 236 | 0.63 | 1750 | 0.59 | 447 | 0.45 | 562 | 0.45 | 725 | 0.52 | <0.001 |
| Nonfatal MI | 7501 | 0.96 | 608 | 1.0 | 178 | 0.85 | 379 | 1.0 | 2958 | 0.99 | 928 | 0.92 | 1154 | 0.92 | 1296 | 0.93 | 0.025 |
| Stroke | 27,900 | 3.6 | 2230 | 3.8 | 631 | 3.0 | 1531 | 4.1 | 11,265 | 3.8 | 3327 | 3.3 | 4076 | 3.2 | 4840 | 3.5 | <0.001 |
| HF | 8335 | 1.1 | 739 | 1.3 | 200 | 1.0 | 479 | 1.3 | 3319 | 1.1 | 1060 | 1.1 | 1141 | 0.91 | 1397 | 1.0 | <0.001 |
| Coronary revascularization | 150 | 0.02 | 11 | 0.02 | 3 | 0.01 | 6 | 0.02 | 74 | 0.02 | 20 | 0.02 | 16 | 0.01 | 20 | 0.01 | 0.189 |
Abbreviations: HF, heart failure; MACE, major adverse cardiovascular event; MI, myocardial infarction.
*
p value was obtained using the χ 2 test.